Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miia Turpeinen

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Drug Metabolism and Drug Interactions|November 16, 2012
Cytochrome P450 2B6: function, genetics, and clinical relevanceMiia Turpeinen, Ulrich M Zanger
Rapid Communications in Mass Spectrometry : RCM|July 20, 2007
Identification of bupropion urinary metabolites by liquid chromatography/mass spectrometryAleksanteri Petsalo, Miia Turpeinen, Ari Tolonen
Journal of Environmental Science and Health. Part. B, Pesticides, Food Contaminants, and Agricultural Wastes|February 26, 2010
An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomesKhaled Abass, Miia Turpeinen, Olavi Pelkonen
Duodecim; Laaketieteellinen Aikakauskirja|December 16, 2017
New study designs in clinical drug developmentOlli Tenhunen, Miia Turpeinen, Pekka Kurki
Current Drug Metabolism|November 1, 2006
The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silicoMiia Turpeinen, Hannu Raunio, Olavi Pelkonen
Frontiers in Pharmacology|February 4, 2020
The Risks and Outcomes Resulting From Medication Errors Reported in the Finnish Tertiary Care Units:: A Cross-Sectional Retrospective Register StudyOuti Laatikainen, Sami Sneck, Miia Turpeinen
Clinical Pharmacokinetics|July 12, 2011
In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directionsOlavi Pelkonen, Miia Turpeinen, Hannu Raunio
Drug Discovery Today|December 9, 2008
Liquid chromatography-mass spectrometry in in vitro drug metabolite screeningAri Tolonen, Miia Turpeinen, Olavi Pelkonen
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 21, 2010
Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomesJuho Hokkanen, Ari Tolonen, Sampo Mattila, et al.
Clinical Pharmacology and Therapeutics|June 25, 2020
Single-Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations Between 2010 and 2019Olli Tenhunen, Florian Lasch, Anja Schiel, et al.
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Drug Metabolism and Drug Interactions|November 16, 2012
Cytochrome P450 2B6: function, genetics, and clinical relevanceMiia Turpeinen, Ulrich M Zanger
Rapid Communications in Mass Spectrometry : RCM|July 20, 2007
Identification of bupropion urinary metabolites by liquid chromatography/mass spectrometryAleksanteri Petsalo, Miia Turpeinen, Ari Tolonen
Journal of Environmental Science and Health. Part. B, Pesticides, Food Contaminants, and Agricultural Wastes|February 26, 2010
An evaluation of the cytochrome P450 inhibition potential of selected pesticides in human hepatic microsomesKhaled Abass, Miia Turpeinen, Olavi Pelkonen
Duodecim; Laaketieteellinen Aikakauskirja|December 16, 2017
New study designs in clinical drug developmentOlli Tenhunen, Miia Turpeinen, Pekka Kurki
Current Drug Metabolism|November 1, 2006
The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silicoMiia Turpeinen, Hannu Raunio, Olavi Pelkonen
Frontiers in Pharmacology|February 4, 2020
The Risks and Outcomes Resulting From Medication Errors Reported in the Finnish Tertiary Care Units:: A Cross-Sectional Retrospective Register StudyOuti Laatikainen, Sami Sneck, Miia Turpeinen
Clinical Pharmacokinetics|July 12, 2011
In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directionsOlavi Pelkonen, Miia Turpeinen, Hannu Raunio
Drug Discovery Today|December 9, 2008
Liquid chromatography-mass spectrometry in in vitro drug metabolite screeningAri Tolonen, Miia Turpeinen, Olavi Pelkonen
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 21, 2010
Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomesJuho Hokkanen, Ari Tolonen, Sampo Mattila, et al.
Clinical Pharmacology and Therapeutics|June 25, 2020
Single-Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations Between 2010 and 2019Olli Tenhunen, Florian Lasch, Anja Schiel, et al.
Pageof 7